SavedAdd your journal

Journals / Tüberküloz ve Toraks / 2020 / Cilt: 68 - Sayı: 3

What is the role of montelukast in asthma treatment?

Astım tedavisinde montelukastın yeri nedir?

Kurtuluş AKSU
Funda AKSU
Pages
328–330
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Antileukotrienes are alternative controller drugs in management of asthma especially in patients who cannot use inhaled glucocorticoids effectively due to compliance problems or poor inhaler techniques.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Asthma is a common chronic pulmonary disease worldwide.
📊
Key Findings & Data:Inhaled glucocorticoids are the most effective therapeutic agents in treatment of asthma and are therefore the first drug of choice in asthma treatment.
💡
Conclusion & Impact:Antileukotrienes are alternative controller drugs in management of asthma especially in patients who cannot use inhaled glucocorticoids effectively due to compliance problems or poor inhaler techniques.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Asthma is a common chronic pulmonary disease worldwide. Inhaled glucocorticoids are the most effective therapeutic agents in treatment of asthma and are therefore the first drug of choice in asthma treatment. Antileukotrienes are alternative controller drugs in management of asthma especially in patients who cannot use inhaled glucocorticoids effectively due to compliance problems or poor inhaler techniques.

Özet

Astım tüm dünyada en yaygın kronik hastalıklardan biri olup, inhale glukokortikosteroidler astım tedavisinde en etkin, dolayısıyla ilk seçenek tedavi yöntemidir. Tedavide ilk seçenek olmayan antilökotrienlerin, inhale glukokortikosteroidlere uyum sorunu olan veya inhaler tekniği doğru uygulayamayan hastalarda birinci basamak kontrol edici ajan olarak kullanılmaları mantıklıdır.

🔖

Cite This Article

AKSU, K., AKSU, F. (2022). What is the role of montelukast in asthma treatment?. Tüberküloz ve Toraks, Cilt: 68 - Sayı: 3, 328–330. https://ajindex.com/articles/618381

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Erişim tarihi: 29 Haziran 2020. Available from: www.ginasthma.org 2. Cabieses B, Uphoff E, Pinart M, Antó JM, Wright J. A systematic review on the development of asthma and allergic diseases in relation to international immigration: the leading role of the environment confirmed. PLoSOne. 2014
  2. 9(8): e105347. 3. Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma. Lancet 2018
  3. 391(10122): 783-800. 4. Kurt E, Metintas S, Basyigit I, Bulut I, Coskun E, Dabak S, et al. Prevalence and risk factors of allergies in Turkey (PARFAIT): results of a multicentre cross-sectional study in adults. Eur Respir J 2009
  4. 33(4): 724-33. 5. Peters-Golden M, Henderson Jr WR. Leukotrienes. N Engl J Med 2007
  5. 357(18): 1841-54. 6. Drazen JM, O’Brien J, Sparrow D, Weiss ST, Martins MA, Israel E, et al. Recovery of leukotriene E4 from the urine of patients with airway obstruction. Am Rev Respir Dis 1992
  6. 146(1): 104-8. 7. Antczak A, Montuschi P, Kharitonov S, Gorski P, Barnes PJ. Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma. Am J Respir Crit Care Med 2002
  7. 166(3): 301-6. 8. Reiss TF, Hill JB, Harman E, Zhang J, Tanaka WK, Bronsky E, et al. Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. Thorax 1997
  8. 52(12): 1030-5. 9. Miligkos M, Bannuru RR, Alkofide H, Kher SR, Schmid CH, Balk EM. Leukotriene-receptor antagonists versus placebo in the treatment of asthma in adults and adolescents: a systematic review and meta-analysis. Ann Intern Med 2015
  9. 163(10): 756-67. 10. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med 1998
  10. 158(11): 1213-20. 11. Bisgaard H, Zielen S, Garcia-Garcia ML, Johnston SL, Gilles L, Menten J, et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med 2005
  11. 171(4): 315-22. 12. Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N, et al. Montelukast, a leukotrienereceptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001
  12. 108(3): e48. 13. Chauhan BF, Ducharme FM. Anti-leukotriene